Exhibit 21.1

Athenex, Inc.

September 30, 2017

Subsidiary Companies	Jurisdiction of Incorporation	Ownership
Athenex API Limited	Hong Kong		100	%
Athenex Biomedical International Holdings Limited	Hong Kong		100	%
Athenex HK Innovative Limited	Hong Kong		100	%
Athenex Manufacturing China Limited	British Virgin Islands		100	%
Athenex Pharma Solutions, LLC	Delaware		100	%
Athenex Pharmaceutical Division, LLC	Delaware		100	%
Athenex Pharmaceuticals (China) Limited	Hong Kong		100	%
Athenex Pharmaceuticals (Chongqing) Limited	People’s Republic of China		100	%
Athenex Pharmaceuticals (Hong Kong) Limited	Hong Kong		100	%
Athenex Pharmaceuticals International Holdings Limited	Hong Kong		100	%
Athenex Pharmaceuticals LLC	New York		100	%
Athenex R&D LLC	Delaware		100	%
Athenex Therapeutics Limited	Hong Kong		100	%
AtheSino Holdings Limited	British Virgin Islands		100	%
Bioksy Investments Ltd.	British Virgin Islands		100	%
Chongqing MJ Medical Devices Co., Ltd.	People’s Republic of China		63.3	%
Chongqing MJ Medical Sciences Co., Ltd.	People’s Republic of China		95	%
Chongqing Taihao Pharmaceutical Co., Ltd.	People’s Republic of China		100	%
Chongqing Taurus Pharmaceutical Co., Ltd.	People’s Republic of China		100	%
Comprehensive Drug Enterprises Limited	Hong Kong		100	%
Excel Bloom Limited	British Virgin Islands		100	%
Golden Wood Limited	Hong Kong		100	%
Maxinase Life Sciences Limited	Hong Kong		100	%
Meridian East Limited	British Virgin Islands		100	%
MJ Medical Gel Systems Limited	Hong Kong		95	%
Polygum Technologies Limited	Hong Kong		25	%
Polymed Therapeutics, Inc.	Texas		100	%
Renascence Therapeutics Limited	Hong Kong		29	%